An interventional study of SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. and MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. in Hypertension (HTN), sponsored by Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata. Recruiting at 1 site in Argentina. Open to participants aged 30 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Hypertension with a site in Argentina — 12 open to participants now, 18 under way, 9 of them phase 3. Hypertension · Argentina.
Among the 74 studies in Hypertension with a site in Argentina, this one is the 65th largest by planned enrollment of the 68 interventional ones that give a count, is one of 10 that started in 2025, is one of 13 with no phase, reaches primary completion later than 3 of the 17 other live ones, and was the 70th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →12 of the 74 studies in Hypertension with a site in Argentina are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Argentina, United States, Japan and 1 more country
Ages 18+
Alnylam Pharmaceuticals · Sites in Argentina, United States, Australia and 32 more countries
Ages 18+
Boehringer Ingelheim · Sites in Argentina, United States, Australia and 48 more countries
Ages 18+
AstraZeneca · Sites in Argentina, United States, Australia and 39 more countries
Ages 18+
Cardiovascular Research Center Rosario British Sanatorium · Sites in Argentina
Ages 65+ · Healthy volunteers
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 30 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 41 · Phase 4 6
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 674 across the 68 interventional studies, 1,075 across the 6 observational. Of the 53 that completed or were terminated, 33 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 74 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata as lead sponsor.
Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
10 of the studies in Hypertension with a site in Argentina that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07424118Evelyn Vanina ReREMIDEP-HTA Program for Hypertension Remission and Medication Deprescription | 2026-11 |
Add all 10 to your calendar (.ics) → With an account.
Among the 74 studies in Hypertension with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized clinical trial aims to compare two cardiorespiratory exercise training protocols - Sprint Interval Training (SIT), characterized by short, maximal-intensity efforts, versus Moderate-Intensity Continuous Training (MICT) - in patients with arterial hypertension. The primary objective is to evaluate the impact of both interventions on 24-hour ambulatory systolic blood pressure (ABPM) after a 12-week training period.
Secondary outcomes include diastolic, daytime, and nighttime blood pressure, metabolic and hemodynamic parameters, body composition, and serum myokine levels (IL-6 and α-CGRP).
Participants aged 30-59 years with diagnosed hypertension but without high cardiovascular risk will be recruited from the Cardio-Metabolic Disease Unit of Hospital San Martín (La Plata, Argentina). After a two-week familiarization period, eligible participants will be randomized to SIT or MICT groups.
The intervention will last 12 weeks, with three supervised sessions per week. The study will provide valuable information about the effectiveness, safety, and clinical applicability of brief, high-intensity exercise for blood pressure control in hypertensive patients.
Introduction
Cardiovascular disease remains the leading cause of mortality worldwide, with hypertension as a major modifiable risk factor. Exercise is a key non-pharmacological strategy for blood pressure management. While moderate-intensity continuous training (MICT) is well established, Sprint Interval Training (SIT) - characterized by short (10-30 s) bursts of maximal effort - has shown promising metabolic and cardiovascular benefits with significantly shorter session durations.
Despite growing interest, few clinical trials have evaluated SIT in hypertensive populations using ambulatory blood pressure monitoring (ABPM), which provides better prognostic information than office measurements. Furthermore, the biological mechanisms underlying exercise-induced benefits may involve myokines such as interleukin-6 (IL-6) and α-calcitonin gene-related peptide (α-CGRP), both associated with improved cardiometabolic health.
Objectives
Primary objective:
To compare the effect of SIT versus MICT on 24-hour systolic ambulatory blood pressure after 12 weeks of structured exercise.
Secondary objectives:
Assess changes in diastolic, daytime, and nighttime ambulatory blood pressure.
Evaluate office BP, anthropometric variables (weight, waist circumference, body fat percentage), and metabolic profile (lipids, glucose, TG/HDL ratio).
Assess changes in maximal oxygen consumption (VO₂max), non-invasive hemodynamic parameters, and handgrip strength.
Determine post-training serum concentrations of IL-6 and α-CGRP as biomarkers of exercise response.
Analyze acute hemodynamic responses and adherence to training.
Materials and Methods
Design:
Open-label, randomized, parallel-group clinical trial with pre- and post-intervention evaluations.
Population:
Hypertensive adults (30-59 years) attending the Cardio-Metabolic Disease Unit of Hospital San Martín (La Plata, Argentina).
Inclusion criteria:
Confirmed hypertension (treated or untreated).
BMI 18.5-34.9 kg/m².
Exclusion criteria:
Office BP ≥160/100 mmHg.
Diabetes, chronic kidney disease (eGFR \<60 mL/min), coronary or cerebrovascular disease, pregnancy, or severe comorbidities.
Intervention:
Participants undergo a 2-week familiarization phase before randomization into two groups:
MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session.
SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session.
Both groups train three times per week for 12 weeks, under professional supervision. Blood pressure, heart rate, and oxygen saturation will be monitored during sessions for safety.
Evaluations:
At baseline and post-intervention:
Office and 24-hour ABPM measurements.
Anthropometry and laboratory tests (lipid profile, glucose, IL-6, α-CGRP via ELISA).
Impedance cardiography and pulse wave velocity for non-invasive hemodynamics.
Graded exercise test to determine VO₂max.
Handgrip strength test.
Sample size:
A total of 14-20 participants (7-10 per group) are required to detect a 5 mmHg difference in 24-hour systolic BP with 80% power and α=0.05.
Statistical analysis:
Between-group comparisons will use t-tests or Wilcoxon rank-sum tests depending on data distribution. Within-group pre/post differences will be analyzed with paired tests. Analyses will follow the intention-to-treat principle, with additional per-protocol analysis for participants achieving ≥75% adherence.
Ethics:
The study is classified as minimal risk and adheres to the Declaration of Helsinki (2024). Approved by the Ethics Committee of Hospital San Martín de La Plata (Reg. No. 070/2019). All participants will provide written informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hypertension will be defined as:
Those patients who report a history of hypertension and are under pharmacological treatment for it (Angiotensin Converting Enzyme Inhibitors/Angiotensin II Receptor Antagonists/Calcium Channel Blockers/Thiazide Diuretics/Beta Blockers) at the time of the evaluation.
OR
Exclusion Criteria:
Elimination Criteria
-Patients whose pharmacological treatment is initiated or modified during the follow-up after 3 months.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session
Behavioral: MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session.
SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session.
Behavioral: SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session.
SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. Three times per week for 12 weeks
MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. three times per week for 12 week
To evaluate the differences between both exercise protocols in 24-hour systolic ambulatory blood pressure (ABPM) values after the 12-week programmed exercise
Time frame: after the 12-week programmed exercise
To evaluate the differences between both exercise protocols in 24-hour diastolic ambulatory blood pressure (ABPM) values after the 12-week programmed exercise
Time frame: after the 12-week programmed exercise
To evaluate the differences between both exercise protocols in daytime and nighttime ambulatory ABPM values after the 12-week programmed exercise.
Time frame: after the 12-week programmed exercise
To evaluate the differences in other clinical characteristics such as office SBP and DBP, weight, waist circumference, and percentage of body fat through skinfold thickness measurements after the 12-week programmed exercise.
Time frame: after the 12-week programmed exercise.
To evaluate the differences between both exercise protocols in insulin resistance and lipid profile parameters (TG/HDL, TG/glycemia, glycemia, LDL) after the 12-week programmed exercise
Time frame: after the 12-week programmed exercise
To evaluate the differences between both exercise protocols in maximal oxygen uptake capacity (Vo2max) after the 12-week programmed exercise
Time frame: after the 12-week programmed exercise
To evaluate the differences between both exercise protocols in noninvasive hemodynamics (peripheral resistance/cardiac index) after the 12-week programmed exercise
Time frame: after the 12-week programmed exercise
To determine plasma levels of interleukin-6 and calcitonin gene-related peptide alpha after the 12-week programmed exercise.
Time frame: after the 12-week programmed exercise.
Plan to share: Undecided — Potentially yes, given the conditions of anonymity as well as the instances of prior agreement and grounds for the reques
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 19 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.